Finch Therapeutics price target lowered to $7 from $17 at H.C. Wainwright

H.C. Wainwright analyst Vernon Bernardino lowered the firm’s price target on Finch Therapeutics to $7 from $17 and keeps a Buy rating on the shares post the Q4 results. Finch reduced its workforce by 95% and withdrew its Investigational New Drug application for CP101, the analyst tells investors in a research note. The firm believes CP101 remains a "high-value asset that would retain significant potential for further development by a future partner."